The formulation involves producing a solid amorphous dispersion of MB-204 using a simple, FDA approved excipient that has improved drug exposures by at least a factor of 20-fold. Improving oral bioavailability results in reduced amounts of drug needed to achieve a target dose which could in turn reduce costs and/or side effects.
“We are very pleased with the results and the efforts of Catalent, Inc.,” said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. ”This represents yet another important milestone for Marvel. The Company is moving quickly to produce enough formulated material to begin our 4-week GLP toxicology, and in parallel, we are set to begin the cGMP manufacturing of MB-204. We remain committed to advancing MB-204 to the clinic in the next two quarters.”
Investor Relations: Marvel Biosciences Corp.
Virtus Advisory Group Roderick (Rod) Matheson, Chief Executive Officer or
Tel: 416-644-5081 Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Email: firstname.lastname@example.org Email: email@example.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.